About Vybion

Vybion, Inc was formed in 2008 following the successful sale of assets in Viral Therapeutics. Vybion’s Intrabody drug platform technology serves as a core development platform. The Company developed a collaboration with the late Paul Patterson of Caltech for neurodegenerative diseases resulting in a family of Intrabodies from which the lead, INT41 was selected for preclinical development.

Viral Therapeutics developed and commercialized critical reagents for diagnostic products in infectious diseases and, as a CRO, developed numerous biologic drugs from bench to IND.